Table 1. Patient- and Transplantation-Characteristics.

Variable		Total Study Group
Year of Transplant	1995-1999	16 (13%)
	2000-2006	40 (32%)
	2007-2013	68 (55%)
Age of Patients	< 50	41 (33%)
	50-60	47 (38%)
	>60	36 (29%)
Median (range) (IQR)		55 (18-72), (47-62)
Patient Gender	Male	83 (67%)
KPS	<90	25 (21%)
	90/100	97 (80%)
Recipient CMV Serostatus	Negative	57 (46%)
	Positive	67 (54%)
Donor Type	RD/URD Match	67 (54%)
	RD/URD MM	8 (7%)
	UCB 5+6/6	24 (19%)
	UCB 4/6	25 (20%)
Conditioning	MAC	47 (38%)
	RIC: w/ ATG	52 (42%)
	RIC: w/o ATG	25 (20%)
GvHD Prophylaxis	CSA/MMF	75 (61%)
	CSA containing	31 (25%)
	Other	18 (15%)
Diagnosis	MDS-NOS	24 (19%)
	MDS - RA	5 (4%)
	MDS - RAEB-1	34 (27%)
	MDS - RAEB-2	30 (24%)
	MDS - RARS	4 (3%)
	MDS - RCMD	21 (17%)
	RCMD - RS	6 (5%)
Months from Diagnosis to Transplant:	Median (range), (IQR)	6 (1-371), (4-13)
Therapy-related MDS	No	94 (77%)
	Yes	28 (23%)
Blast at alloHCT	<=2%	74 (60%)
	>2-<5%	33 (27%)
	5-10%	17 (14%)

Abbreviations: AlloHCT, allogeneic hematopoietic cell transplantation; CMV, cytomegalovirus; CSA, cyclosporine; GVHD, graft-versus-host disease; IPSS, International Prognostic Scoring System; R-IPSS, International Prognostic Scoring System-revised; KPS, Karnofsky performance status; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MDS-U, MDS- unclassifiable; MRD, matched related donor; MMRD, mismatched related donor; MTX, methotrexate; RIC, reduced intensity conditioning; MMF, mycophenolate mofetil; MDS, myelodysplastic syndrome; NOS, not otherwise specified; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RARS, refractory anemia with ringed sideroblasts; RD, related donor; RCMD, refractory cytopenias with multilineage dysplasia; RCMD/RS, RCMD with ringed sideroblasts; UCB, umbilical cord blood; URD, unrelated donor; WHO, World Health Organization